Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-04-21 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
董事、监事和高级管理人员所持本公司股份及其变动管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for the holdings and changes of shares by directors, supervisors, and senior management of the company. It details rules and regulations regarding shareholding, trading restrictions, reporting, disclosure, and account management for these insiders. It references relevant laws and stock exchange rules but does not contain financial statements, earnings data, or audit information. It is a governance-related document focusing on internal rules and compliance for insider share transactions. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a mere announcement or certification, so it is not RPA or RNS.
2022-04-21 Chinese
2021 年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放与使用情况的专项报告" which translates to "2021 Annual Report on the Storage and Use of Raised Funds". It details the amount of funds raised, their usage, storage, management, and compliance with regulatory requirements. It includes specific financial figures related to fundraising, usage, and balances as of December 31, 2021. The document also contains auditor's verification and sponsor's opinions on the use of the raised funds. The content is focused on the company's capital raising activities and the management of those funds, rather than a general annual report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and detailed, not merely an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is CAP with high confidence.
2022-04-21 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report Summary" of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It contains detailed company information, business overview, core technologies, product and production plans, financial data including main accounting data and financial indicators for the year 2021, quarterly data, shareholder information, and future outlook. The length is substantial (over 14,000 characters) and includes comprehensive financial and operational details typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-21 Chinese
关于2022年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (292 characters) stating that the company's 2022 first quarter report has been disclosed on an official website. It does not contain the actual financial data or detailed report content but merely informs investors where to find the report. According to the 'MENU VS MEAL' rule, such a brief notice about report disclosure is classified as a Report Publication Announcement (RPA).
2022-04-21 Chinese
关于新乡拓新药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (Special Audit Report) concerning the summary table of non-operating fund occupation and other related party fund transactions for the year 2021 of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes an audit opinion by a registered CPA firm, referencing the 2021 financial statements and compliance with regulatory requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. The document contains detailed audit findings and a summary table of related party transactions, but it is not a full annual report or interim report. It is a standalone audit report focusing on a specific aspect of the company's financials, namely related party fund transactions and non-operating fund occupation. The document length is about 2561 characters, which is relatively short but contains substantive audit content and tables. It is not a mere announcement or certification letter. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2021
2022-04-21 Chinese
新乡拓新药业股份有限公司内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It is issued by an auditing body and addresses the effectiveness of internal controls related to financial statements as of December 31, 2021. The content includes detailed descriptions of internal control objectives, principles, risk assessments, control activities, and supervision. It is a standalone report focused on internal control evaluation rather than a full annual report or financial statement. The document is not a brief announcement or a certification letter but a comprehensive assurance report on internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.